Literature DB >> 26398825

Central Nervous System Pseudoprogression in a Patient Treated with PD-1 Checkpoint Inhibitor.

Mark K Doherty1, Kevin Jao, Frances A Shepherd, Lili-Naz Hazrati, Natasha B Leighl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26398825     DOI： 10.1097/JTO.0000000000000587

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  13 in total

Review 1.  Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives.

Authors:  Grainne M O'Kane; Natasha B Leighl
Journal:  Transl Lung Cancer Res       Date:  2016-12

2.  Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer.

Authors:  Matthew J Bott; Stephen C Yang; Bernard J Park; Prasad S Adusumilli; Valerie W Rusch; James M Isbell; Robert J Downey; Julie R Brahmer; Richard Battafarano; Errol Bush; Jamie Chaft; Patrick M Forde; David R Jones; Stephen R Broderick
Journal:  J Thorac Cardiovasc Surg       Date:  2018-12-13       Impact factor: 5.209

Review 3.  Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.

Authors:  Grainne M O'Kane; Catherine Labbé; Mark K Doherty; Kelvin Young; Hamzeh Albaba; Natasha B Leighl
Journal:  Oncologist       Date:  2016-08-17

4.  Rapid Progressive Disease After Nivolumab Therapy in Three Patients with Metastatic Renal Cell Carcinoma.

Authors:  Yuki Kobari; Tsunenori Kondo; Toshio Takagi; Kenji Omae; Hayakazu Nakazawa; Kazunari Tanabe
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

5.  Expectoration of tonsillar metastasis of pulmonary pleomorphic carcinoma after pseudoprogression: A case report.

Authors:  Tomoki Kuge; Fukuko Okabe; Yuji Yamamoto; Mikako Ishijima; Takeshi Uenami; Masaki Kanazu; Yuki Akazawa; Yukihiro Yano; Toshihiko Yamaguchi; Masahide Mori
Journal:  Thorac Cancer       Date:  2021-05-11       Impact factor: 3.500

6.  Effect of Gamma Knife Radiosurgery and Programmed Cell Death 1 Receptor Antagonists on Metastatic Melanoma.

Authors:  Nathan Nordmann; Molly Hubbard; Tyler Nordmann; Paul W Sperduto; H Brent Clark; Matthew A Hunt
Journal:  Cureus       Date:  2017-12-13

7.  Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab.

Authors:  Coraline Dumenil; Marie-Ange Massiani; Jennifer Dumoulin; Violaine Giraud; Sylvie Labrune; Thierry Chinet; Etienne Giroux Leprieur
Journal:  PLoS One       Date:  2018-04-23       Impact factor: 3.240

Review 8.  Immune response evaluation criteria in solid tumors for assessment of atypical responses after immunotherapy.

Authors:  Davide Ippolito; Cesare Maino; Maria Ragusi; Marco Porta; Davide Gandola; Cammillo Talei Franzesi; Teresa Paola Giandola; Sandro Sironi
Journal:  World J Clin Oncol       Date:  2021-05-24

Review 9.  Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?

Authors:  Lizza E L Hendriks; Jordi Remon; Jessica Menis; Benjamin Besse
Journal:  Transl Lung Cancer Res       Date:  2021-06

10.  Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports.

Authors:  Stefan Schliep; Abbas Agaimy; Alexander Cavallaro; Franklin Kiesewetter; Gerold Schuler; Lucie Heinzerling
Journal:  J Immunother Cancer       Date:  2018-01-15       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.